Peregrine initiates dosing in Phase II lung cancer trial
July 2nd, 2008
Peregrine Pharmaceuticals has initiated patient screening and dosing in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer.